Monte Rosa Therapeutics (GLUE) Operating Leases: 2023-2025
Historic Operating Leases for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $35.9 million.
- Monte Rosa Therapeutics' Operating Leases fell 10.30% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year decrease of 10.30%. This contributed to the annual value of $39.0 million for FY2024, which is 9.04% down from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Operating Leases is $35.9 million, which was down 3.00% from $37.0 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Operating Leases registered a high of $44.4 million during Q2 2023, and its lowest value of $35.9 million during Q3 2025.
- Its 3-year average for Operating Leases is $40.6 million, with a median of $40.9 million in 2024.
- Data for Monte Rosa Therapeutics' Operating Leases shows a maximum YoY fell of 10.30% (in 2025) over the last 5 years.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Operating Leases stood at $42.9 million in 2023, then decreased by 9.04% to $39.0 million in 2024, then fell by 10.30% to $35.9 million in 2025.
- Its last three reported values are $35.9 million in Q3 2025, $37.0 million for Q2 2025, and $38.0 million during Q1 2025.